Searchable abstracts of presentations at key conferences in endocrinology

ea0037oc2.3 | Reproduction | ECE2015

Restoration of fertility in hypogonadal LH receptor null background male mice by a constitutive active mutant FSH receptor

Oduwole Olayiwola , Peltoketo Hellevi , Poliandri Ariel , Vengadabady Laura , Huhtaniemi Ilpo

The gonadotropic hormones, LH and FSH are critical regulators of normal sexual functions including steroidogenesis and gametogenesis. Their essential role is underscored by the development of various hypogonadal phenotypes arising from genetic mutations. Constitutive activation of their cognate receptors also disturbs their function. We earlier showed that transgenic expression of an activating mouse Fshr mutant (mFSHRD580H) in granulosa c...

ea0034p247 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2014

Maternal metabolic adaptations in pregnancy are associated with altered circadian rhythmicity

Papacleovoulou Georgia , Nikolova Vanya , Oduwole Olayiwola , Parker Malcolm , Williamson Catherine

Introduction: Pregnancy is associated with maternal metabolic adaptations (increased cholesterol and triglycerides) that are essential for the development and maintenance of the fetus. Physiological and behavioural changes are driven via biological clocks entrained by the light–dark/rest–activity cycles that define feeding time and body temperature. A number of oscillators are present in the peripheral organs that are synchronised by cues from the suprachiasmatic nuc...

ea0041gp117 | Endocrine Tumours | ECE2016

FSH supplementation increases the growth of PC-3 human prostate cancer cell xenograft in gonadotropin-suppressed nude mice

Oduwole Olayiwola , Poliandri Ariel , Rawson Phil , Rahman Nafis , Koechling Wolfgang , Huhtaniemi Ilpo

Gonadotropin-releasing hormone (GnRH) analogues are now the standard hormonal treatment for prostate cancer. A fundamental difference between GnRH agonist and antagonist treatment is the permanent suppression of both gonadotropins (LH and FSH) by antagonist, while a rebound in FSH is associated with agonist treatment. The benefits of antagonist include the immediate onset of action and profound long-term suppression of FSH, suggested to be an independent growth factor in prost...